P164 Physician's considerations for re-biopsy in patients with recurrent metastatic breast cancer
Shlomit Strulov Shachar(Tel Aviv Sourasky Medical Center), Gil Bar‐Sela(Emek Medical Center), Noa Shafran(Technion – Israel Institute of Technology), Georgeta Fried(Roche (Switzerland)), Karen Drumea(Rambam Health Care Campus)
Cited by 0
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
|Nature Medicine|2019|328